{"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}],"groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until \\> 5 x 10\\^6 CD34+/kg has been collected.\n\n.\n\nbendamustine hydrochloride: Given IV\n\ndexamethasone: Given PO\n\nfilgrastim: Given SC\n\nleukapheresis: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nflow cytometry: Correlative studies\n\netoposide: Given IV","id":"BG000","title":"Treatment (Chemotherapy and Colony-stimulating Factor)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"70","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}